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Abstract
Epidemiologic studies report a protective association between non-steroidal anti-inflammatory 
drug (NSAID) use and hormone receptor-positive breast cancer risk, a finding consistent with 
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NSAID-mediated suppression of aromatase-driven estrogen biosynthesis. However, the 
association between NSAID use and breast cancer-specific mortality is uncertain and it is 
unknown whether this relationship differs by hormone receptor status. This study comprised 935 
invasive breast cancer cases, of which 490 were estrogen receptor (ER)-positive, enrolled between 
1996 and 2001 in the Carolina Breast Cancer Study. Self-reported NSAID use in the decade prior 
to diagnosis was categorized by duration and regularity of use. Differences in tumor size, stage, 
node, and receptor status by NSAID use were examined using Chi-square tests. Associations 
between NSAID use and breast cancer-specific mortality were examined using age- and race-
adjusted Cox proportional hazards analysis. Tumor characteristics did not differ by NSAID use. 
Increased duration and regularity of NSAID use was associated with reduced breast cancer-
specific mortality in women with ER-positive tumors (long-term regular use (≥8 days/month for ≥ 
3 - years) versus no use; hazard ratio (HR) 0.48; 95 % confidence interval (CI) 0.23–0.98), with a 
statistically significant trend with increasing duration and regularity (p-trend = 0.036). There was 
no association for ER-negative cases (HR 1.19; 95 %CI 0.50–2.81; p-trend = 0.891). Long-term, 
regular NSAID use in the decade prior to breast cancer diagnosis was associated with reduced 
breast cancer-specific mortality in ER-positive cases. If confirmed, these findings support the 
hypothesis that potential chemopreventive properties of NSAIDs are mediated, at least in part, 
through suppression of estrogen biosynthesis.
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Introduction
Non-steroidal anti-inflammatory drug (NSAID) use is associated with 10–20 % reduced risk 
of breast cancer [1–3], with similar effect estimates for aspirin use alone [1–5]. A previous 
analysis using data from the Carolina Breast Cancer Study reported that NSAID use was 
associated with reduced breast cancer incidence [6], and several other epidemiologic studies 
have reported that this protective effect of NSAID use on breast cancer risk is strongest for 
hormone receptor-positive tumors [7–10].
The anti-inflammatory properties of NSAIDs are mediated via cyclooxygenase (COX) 
inhibition which in turn reduces prostaglandin levels, resulting in down-regulation of the 
aromatase pathway and decreased estrogen biosynthesis [11, 12]. The inverse association 
between NSAID use and risk of hormone receptor-positive breast cancer is consistent with 
this NSAID-mediated suppression of estrogen biosynthesis. However, evidence for an 
association between NSAID use and breast cancer-specific mortality is conflicting. 
Although one study reported that aspirin use was associated with reduced breast cancer-
specific mortality [13], three studies reported no association between NSAID or aspirin use 
and breast cancer-specific mortality [14–16]. Only a single study examined the association 
between aspirin use and breast cancer-specific mortality by estrogen receptor (ER) status 
and found no evidence of differential effects by ER status [13]. Notably, these studies were 
limited by small numbers of breast cancer-specific deaths [14, 16], incomplete NSAID 
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exposure assessment, focusing on aspirin and/or ibuprofen use only [13, 16], or examination 
of regularity of NSAID use without taking duration of use into account [14].
The objective of this current study was to examine the association between use of 
prescription and non-prescription NSAIDs and breast cancer-specific mortality within the 
population-based Carolina Breast Cancer Study. Given evidence that NSAIDs reduce 
estrogen biosynthesis via inhibition of aromatase activity, we hypothesized that there would 
be a stronger protective association between NSAID use and risk of breast cancer-specific 
mortality in women with ER-positive tumors.
Methods
Study population
The Carolina Breast Cancer Study is a population-based, case–control study conducted in 
North Carolina (NC) between 1993 and 2001 [17]. This study was approved by the Office of 
Human Research Ethics at the University of North Carolina at Chapel Hill and informed 
consent was obtained from each participant. The present study includes 935 women with 
invasive breast cancer who were interviewed between 1996 and 2001 and provided 
information on NSAID use. Briefly, cases of invasive breast cancer were identified using 
rapid case ascertainment in cooperation with the NC Central Cancer Registry. All women 
who agreed to participate were interviewed in person by a registered nurse using a 
standardized questionnaire to collect information on established and suspected breast cancer 
risk factors, including prescription and non-prescription medication use. Tumor size, stage, 
and lymph node status were abstracted from medical records. Estrogen receptor (ER) and 
progesterone receptor (PR) status were abstracted from medical records for 80 % of 
participants [18]. For the remaining 20 % of participants, tumor tissue was sectioned and 
stained for ER and PR at the Immunohistochemistry Core Laboratory at the University of 
North Carolina.
Exposure assessment
Women were shown photographs of commonly used NSAIDs and asked to report non-
prescription and prescription NSAID use during the past decade. Assessment of duration and 
regularity of NSAID use is described in detail by Moorman et al. [6]. Briefly, women who 
reported NSAID use ≥8 days a month for ≥3 months were categorized as regular users. 
Regular users were further categorized by duration of use (<3 vs. ≥3 years). Women who 
reported NSAID use <3 months or who reported sporadic use (≤7 days a month) regardless 
of duration were categorized as occasional users. Acetaminophen has a COX-independent 
mechanism of action, so was included in the “no use” category. Women were also asked the 
reason for NSAID use, and could select multiple reasons from a list which included arthritis, 
bursitis or rheumatism, back pain, surgical/dental pain, menstrual cramps, injury, or other.
Outcome assessment
Vital status was determined through December 31, 2011 through linkage with the National 
Death Index, which provided date and cause of death for each individual. Using 
international classification of disease (ICD) codes, we categorized cause of death as either 
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breast cancer-specific (ICD-9 code 174.9 or ICD-10 code 50.9) or other cause of death 
based on the first listed primary cause of death.
Statistical analysis
Age and race were selected a priori to be potential confounders of the association between 
NSAID use and risk of breast cancer-specific mortality. We also considered the following 
variables as potential confounders: education level, body mass index (BMI), and 
menopausal status. Chi-square tests were used to examine the distribution of these potential 
confounders according to NSAID use and to examine differences in tumor characteristics 
between NSAID users and non-users.
Individuals who died of causes other than breast cancer were censored at time of death and 
living individuals were censored on December 31, 2011. We modeled breast cancer-specific 
survival curves according to categories of duration and regularity of NSAID use versus no 
use using the Kaplan–Meier method and we compared survival curves using log-rank 
analysis. The proportional hazards assumption was met for each variable. We then 
conducted Cox proportional hazards analysis to test the association between categories of 
duration and regularity of NSAID use versus no use and risk of breast cancer-specific 
mortality among all invasive cases and within strata defined by hormone receptor status. We 
tested for linear trend with increasing duration and regularity of NSAID use using by 
assigning the median value to each NSAID category. We stratified both by ER status (ER + 
vs. ER–) and by positive hormone receptor status (ER + or PR + vs. ER– and PR–). Hazard 
ratios (HRs) were adjusted for age and race (African American (AA), non-AA). We also 
explored the effect of adjusting HRs for menopausal status (pre-, postmenopausal) and 
education level (< high school, high school graduate, > high school). Given the lack of 
association between NSAID use and BMI in this population, models were not adjusted for 
BMI. All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC). 
Statistical tests were two-sided, and p values < 0.05 were considered statistically significant.
Results
Baseline characteristics of breast cancer cases stratified by NSAID use
The majority of study participants reported NSAID use; 84 (11.5 %) breast cancer survivors 
and 25 (12.1 %) women who died of breast cancer were categorized as non-users. Breast 
cancer cases who reported NSAID use were younger than non-users (p = 0.029), had a 
higher level of education (p = 0.029) and were more likely to be premenopausal (p = 0.029; 
Table 1). There were no differences in race or BMI according to NSAID use (p = 0.259 and 
p = 0.634, respectively).
We compared reasons for NSAID use between categories of duration and regularity of 
NSAID use (Online Resource 1). Relative to occasional users, long-term regular NSAID 
users were significantly more likely to cite chronic conditions including arthritis, bursitis or 
rheumatism (50.3 % of long-term regular users versus 14.8 % of occasional users; p < 
0.0001), and back pain (27.1 % of long-term regular users versus 17.6 % of occasional 
users; p = 0.006) as reasons for NSAID use. Conversely, occasional users were more likely 
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to cite acute conditions including menstrual cramps (18.6 % of occasional users versus 11 % 
of long-term regular users; p = 0.009) and headache (68.2 % of occasional users versus 51.9 
% of long-term regular users; p < 0.0001).
Tumor characteristics of NSAID users
Although there was a suggestion that ER-positive and ER or PR-positive breast cancer was 
less common among NSAID users, these associations were not statistically significant (p = 
0.149 and p = 0.135, respectively; Table 2). There were no strong or significant associations 
between NSAID use and tumor stage, node status or tumor size (all p > 0.5; Table 2).
NSAID use and breast cancer-specific mortality
Overall, 181 (21.9 %) NSAID users and 25 (22.9 %) non-users died of breast cancer (log-
rank p = 0.808; Fig. 1a) during a median follow-up period of 13 years (interquartile range; 
8–14 years). Among all invasive cases, increased duration and regularity of NSAID use was 
not associated with breast cancer-specific mortality on unadjusted analysis (log-rank p = 
0.221; Fig. 1b). After adjusting for age and race, although there was no association between 
NSAID ever use and risk of breast cancer-specific mortality (use versus no use; HR 0.93; 95 
%CI 0.61–1.41; Table 3), there was a suggestion that increasing duration and regularity of 
NSAID use was associated with a reduced hazard ratio of breast cancer-specific mortality, 
although this was not significant (NSAID use ≥8 days/month for ≥3 years versus no use; HR 
0.71; 95 %CI 0.42–1.21; p-trend = 0.105; Table 3).
Among ER-positive cases only (n = 490), 76 (17.8 %) NSAID users and 16 (25.0 %) non-
users died of breast cancer (log-rank p = 0.089; Fig. 1c). Increased duration and regularity of 
NSAID use was not associated with breast cancer-specific mortality on unadjusted analysis 
(log-rank p = 0.141; Fig. 1d). However, after adjusting for age and race, increased duration 
and regularity of NSAID use was significantly associated with a reduced hazard ratio for 
ER-positive breast cancer-specific mortality (regular use ≥3 years versus no use; HR 0.48; 
95 %CI 0.23–0.98; Table 3), with a significant trend across categories of increasing duration 
and regularity of NSAID use (p-trend = 0.036). When duration and regularity categories 
were collapsed to create a single NSAID use category, there was a reduced hazard ratio 
among women with ER-positive tumors (use versus no use; HR 0.63; 95 %CI 0.37–1.09; 
Table 3). In contrast, among women with ER-negative breast cancer, use of NSAIDs had an 
elevated, but imprecise hazard ratio (use versus no use; HR 1.46; 95 %CI 0.71–3.01; Table 
3) and there was no association between increased duration and regularity of NSAID use 
and breast cancer-specific mortality (regular use ≥3 years versus no use; HR 1.19; 95 %CI 
0.50–2.81; p-trend = 0.891). Further adjustment of our models for menopausal status and 
education level had no appreciable effect on our estimates (data not shown). Finally, these 
associations were similar when we stratified women into groups based on both ER and 
progesterone receptor (PR) positivity (ER- or PR-positive versus ER- and PR-negative; data 
not shown).
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Evidence from preclinical models [19, 20] and epidemiologic studies [3] supports a potential 
role for NSAIDs in breast cancer chemoprevention. Using data from the population-based 
Carolina Breast Cancer Study, we found that increasing duration and regularity of NSAID 
use within the decade prior to diagnosis was associated with reduced breast cancer-specific 
mortality in women with ER-positive tumors. This association was not observed among 
women with ER-negative tumors, suggesting that the protective effect of NSAID use on 
breast cancer-specific mortality may be limited to hormone-dependent breast cancer. These 
results are consistent with the hypothesis that the potential chemopreventive and tumor 
suppressive properties of NSAIDs are mediated, at least in part, through suppression of 
estrogen biosynthesis.
NSAIDs inhibit activity of COX-2, a key enzyme in prostaglandin synthesis with an 
established role in inflammation and carcinogenesis [21]. While normal breast tissue 
expresses low levels of COX-2, approximately 40 % of invasive breast tumors overexpress 
this enzyme [11, 22] and elevated levels are associated with increased risk of breast cancer-
specific mortality [23]. Given that COX-2-mediated prostaglandin production promotes 
estrogen biosynthesis via up regulation of the aromatase pathway [12], there is biologic 
rationale to support a role for NSAIDs in ER-positive breast cancer [11]. Indeed, NSAID 
use is associated with reduced serum estradiol levels in women with breast cancer [24], 
which may impact growth of estrogen-responsive tumors. Several studies have found the 
protective effect of NSAID use on breast cancer incidence to be restricted to hormone 
receptor-positive breast cancer [7–9], although others reported no difference in this 
association according to hormone receptor status [25–31].
Few studies have examined the association between NSAID use and breast cancer-specific 
mortality, and only one conducted stratified analysis by ER status [13]. While this prior 
study found no evidence of effect modification by ER status (p-interaction = 0.52), their 
results were limited to assessment of aspirin use only and there was a reduced sample size 
for which ER status was available [13]. In this study, we were able to examine all 
prescription and non-prescription NSAIDs using a population-based dataset of over 900 
incident cases over 13 years of follow-up.
Our results should be considered in light of the study's strengths and limitations. First, 
confounding by indication is an important consideration in observational studies of NSAID 
use. To ascertain whether long-term regular NSAID users were more likely to suffer from 
chronic conditions, we documented the reason for NSAID use. As anticipated, we found that 
long-term regular users were more likely to use NSAIDs to control symptoms of arthritis, 
relative to occasional users. While a possible association between arthritis and increased risk 
of breast cancer-specific mortality has not been consistently reported [32, 33], such an 
association would likely result in uncontrolled bias in our results. However, the direction of 
bias would likely be toward the null and, as such, our analysis may have underestimated the 
strength of the association between long-term regular NSAID use and risk of breast cancer-
specific mortality. Moreover, a previous study found that a diagnosis of arthritis did not 
modify the association between NSAID use and breast cancer risk [25]. Second, we lacked 
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treatment data in Carolina Breast Cancer Study Phase 2, and so could not examine 
interactions between NSAID use and breast cancer treatment. Third, we did not collect 
information on post-diagnosis NSAID use. However, long-term regular users were more 
likely to use NSAIDs to control chronic conditions, suggesting they would be likely to 
continue regular NSAID use post-diagnosis. While occasional users who reported NSAID 
use for menstrual cramps may have been less likely to continue NSAID use if they 
experienced treatment-induced menopause, the majority of occasional users cited headache 
as the reason for NSAID use, and this condition would not be expected to be altered by 
breast cancer diagnosis or treatment. Thus, while we would expect similar patterns of 
NSAID use post-diagnosis, future studies should explore the association between post-
diagnosis NSAID use and risk of breast cancer-specific mortality.
These limitations are balanced by an important strength of this study. Most previous studies 
did not collect complete NSAID use information, focusing solely on aspirin and ibuprofen 
use [13, 15, 16]. Incomplete NSAID use data may attenuate the association between NSAID 
use and breast cancer, since many “unexposed” women may have taken NSAIDs that were 
not ascertained during data collection, particularly given the widespread use of NSAIDs. In 
this study, we attempted to collect complete information on all prescription and non-
prescription NSAID use, and improved recall to the best of our ability by showing 
photographs of commonly used NSAIDs to each participant. This study is also strengthened 
by long follow-up and by inclusion of a large number of African American women, allowing 
our results to be generalized to a diverse population of women.
This is the first study, to our knowledge, to report a protective association between NSAID 
use and breast cancer-specific mortality which is limited to ER-positive tumors. This finding 
is supported by extensive preclinical and epidemiologic evidence for a role of COX-2 
inhibition in ER-positive breast cancer. Several clinical trials in breast cancer patients have 
suggested that combining COX-2 inhibitors with aromatase inhibitors may improve efficacy 
of aromatase inhibitors in patients with ER-positive tumors [34, 35]. However, while these 
trials support a role for targeting COX-2 in breast cancer treatment, the clinical utility of 
selective COX-2 inhibitors is limited due to increased risk of serious cardiovascular events 
[36, 37]. Thus, if confirmed, our results provide additional rationale for exploring a potential 
role for NSAIDs in breast cancer treatment.
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Kaplan—Meier plots showing breast cancer-specific mortality by NSAID use versus no use 
among a all invasive cases and b ER-positive cases, and categories of duration and 
regularity of NSAID use among c all invasive cases and d among ER-positive cases
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Table 1
Characteristics of invasive breast cancer cases in the Carolina Breast Cancer Study Phase 2 according to 
NSAID use




    Non-African American 51 (46.8) 434 (52.5) 0.259
    African American 58 (53.2) 392 (47.5)
Age at selection
    < 40 9 (8.3) 128 (15.5) 0.029
    40-49 37 (33.9) 292 (35.4)
    50-59 22 (20.2) 194 (23.5)
    60-74 41 (37.6) 212 (25.7)
Education
    < High school 27 (24.8) 143 (17.3) 0.029
    High school graduate 35 (32.1) 219 (26.5)
    > High school 47 (43.1) 464 (56.2)
Body mass index (kg/m2)
    < 25 35 (34.0) 259 (31.8) 0.634
    25-29 32 (31.1) 231 (28.4)
    30+ 36 (35.0) 324 (39.8)
    Missing 6 12
Menopausal status
    Premenopausal 39 (35.8) 387 (46.9) 0.029
    Postmenopausal 70 (64.2) 439 (53.1)
*
Chi-square test
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Table 2
Tumor characteristics of invasive breast cancer cases in the Carolina Breast Cancer Study Phase 2 according 
to NSAID use




    Stage I 48 (44.9) 328 (41.5) 0.515
    Stage II 42 (39.3) 355 (44.9)
    Stage III 15 (14.0) 84 (10.6)
    Stage IV 2 (1.9) 23 (2.9)
    Missing 2 36
Node status
    Negative 74 (67.9) 533 (64.7) 0.510
    Positive 35 (32.1) 291 (35.3)
    Missing 0 2
Tumor size
    ≤ 2 cm 52 (50.5) 406 (52.3) 0.939
    > 2–5 cm 38 (36.9) 279 (35.9)
    > 5 cm 13 (12.6) 92 (11.8)
    Missing 6 49
ER status
    Positive 64 (62.1) 426 (54.6) 0.149
    Negative 39 (37.9) 354 (45.4)
    Missing 6 46
ER/PR status
    ER + or PR+ 72 (69.9) 485 (62.3) 0.135
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Table 3
Associations between NSAID use and risk of breast cancer-specific mortality among invasive cases in the 
Carolina Breast Cancer Study Phase 2, overall and stratified by estrogen receptor status
All invasive cases
n, cases (deaths) HR
*
 (95 % CI)
NSAID use
    No use 109 (25) 1.00 (ref)
    Use 826 (181) 0.93 (0.61–1.41)
NSAID regularity and duration of use
    No use 109 (25) 1.00 (ref)
    Occasional 506 (122) 1.02 (0.66–1.59)
    Regular < 3 years 139 (30) 0.90 (0.53–1.53)
    Regular ≥ 3 years 181 (29) 0.71 (0.42–1.21)
        p-trend 0.105
ER-positive cases n, cases (deaths) HR
*
 (95 % CI) ER-negative cases n, cases (deaths) HR
*
 (95 % CI)
NSAID use
    No use 64 (16) 1.00 (ref) 39 (8) 1.00 (ref)
    Use 426 (76) 0.63 (0.37-1.09) 354 (100) 1.46 (0.71-3.01)
NSAID regularity and duration of use
    No use 64 (16) 1.00 (ref) 39 (8) 1.00 (ref)
    Occasional 251 (52) 0.73 (0.41–1.29) 222 (65) 1.56 (0.74–3.28)
    Regular <3 years 63 (10) 0.57 (0.26–1.25) 68 (20) 1.47 (0.65–3.34)
    Regular ≥3 years 112 (14) 0.48 (0.23–0.98) 64 (15) 1.19 (0.50–2.81)
        p-trend 0.036 0.891
*
HRs adjusted for age and race
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